+

WO2012112730A3 - Compositions and methods for delivering nucleic acid to a cell - Google Patents

Compositions and methods for delivering nucleic acid to a cell Download PDF

Info

Publication number
WO2012112730A3
WO2012112730A3 PCT/US2012/025324 US2012025324W WO2012112730A3 WO 2012112730 A3 WO2012112730 A3 WO 2012112730A3 US 2012025324 W US2012025324 W US 2012025324W WO 2012112730 A3 WO2012112730 A3 WO 2012112730A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
cell
nucleic acid
delivering nucleic
Prior art date
Application number
PCT/US2012/025324
Other languages
French (fr)
Other versions
WO2012112730A2 (en
Inventor
Mark E. HAYES
Dmitri B. Kirpotin
Original Assignee
Merrimack Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrimack Pharmaceuticals, Inc. filed Critical Merrimack Pharmaceuticals, Inc.
Priority to JP2013553671A priority Critical patent/JP6054308B2/en
Priority to EP12746634.0A priority patent/EP2675918B1/en
Priority to AU2012217685A priority patent/AU2012217685B2/en
Priority to CA2827118A priority patent/CA2827118A1/en
Publication of WO2012112730A2 publication Critical patent/WO2012112730A2/en
Publication of WO2012112730A3 publication Critical patent/WO2012112730A3/en
Priority to US13/967,664 priority patent/US20140065204A1/en
Priority to US15/004,481 priority patent/US10087464B2/en
Priority to US16/025,503 priority patent/US20190017073A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Manufacturing & Machinery (AREA)

Abstract

Provided are novel compositions useful for delivering nucleic acids to cells. Also provided are methods for making and using such compositions.
PCT/US2012/025324 2011-02-15 2012-02-15 Compositions and methods for delivering nucleic acid to a cell WO2012112730A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP2013553671A JP6054308B2 (en) 2011-02-15 2012-02-15 Compositions and methods for delivering nucleic acids to cells
EP12746634.0A EP2675918B1 (en) 2011-02-15 2012-02-15 Compositions and methods for delivering nucleic acid to a cell
AU2012217685A AU2012217685B2 (en) 2011-02-15 2012-02-15 Compositions and methods for delivering nucleic acid to a cell
CA2827118A CA2827118A1 (en) 2011-02-15 2012-02-15 Compositions and methods for delivering nucleic acid to a cell
US13/967,664 US20140065204A1 (en) 2011-02-15 2013-08-15 Compositions and methods for delivering nucleic acid to a cell
US15/004,481 US10087464B2 (en) 2011-02-15 2016-01-22 Compositions and methods for delivering nucleic acid to a cell
US16/025,503 US20190017073A1 (en) 2011-02-15 2018-07-02 Compositions and methods for delivering nucleic acid to a cell

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161443246P 2011-02-15 2011-02-15
US61/443,246 2011-02-15

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/967,664 Continuation US20140065204A1 (en) 2011-02-15 2013-08-15 Compositions and methods for delivering nucleic acid to a cell

Publications (2)

Publication Number Publication Date
WO2012112730A2 WO2012112730A2 (en) 2012-08-23
WO2012112730A3 true WO2012112730A3 (en) 2013-03-07

Family

ID=46673165

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/025324 WO2012112730A2 (en) 2011-02-15 2012-02-15 Compositions and methods for delivering nucleic acid to a cell

Country Status (6)

Country Link
US (3) US20140065204A1 (en)
EP (1) EP2675918B1 (en)
JP (2) JP6054308B2 (en)
AU (1) AU2012217685B2 (en)
CA (1) CA2827118A1 (en)
WO (1) WO2012112730A2 (en)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
MX2013003681A (en) 2010-10-01 2013-11-20 Moderna Therapeutics Inc Engineered nucleic acids and methods of use thereof.
JP2014511687A (en) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド Engineered nucleic acid delivery and formulation
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2763701B1 (en) 2011-10-03 2018-12-19 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
CA3018046A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
DE18200782T1 (en) 2012-04-02 2021-10-21 Modernatx, Inc. MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH DISEASES IN HUMANS
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
ITRM20120480A1 (en) * 2012-10-09 2014-04-10 Uni Degli Studi Camerino MULTICOMPONENT LIPID NANOPARTICLES AND PROCEDURES FOR THEIR PREPARATION.
JP6144355B2 (en) 2012-11-26 2017-06-07 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． Chemically modified mRNA
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
BR112016007255A2 (en) 2013-10-03 2017-09-12 Moderna Therapeutics Inc polynucleotides encoding low density lipoprotein receptor
CA3177878A1 (en) 2014-04-23 2015-10-29 Modernatx, Inc. Nucleic acid vaccines
AU2015287833B2 (en) 2014-07-08 2018-09-13 The Children's Medical Center Corporation Compositions and methods for treating diabetes
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
DK3302435T3 (en) 2015-05-26 2023-06-06 Plumb Pharmaceuticals Inc LIPO RECHARGING
TWI724018B (en) 2015-08-20 2021-04-11 英商益普生生物製藥有限公司 Combination therapy for cancer treatment
PT3337478T (en) 2015-08-21 2020-10-19 Ipsen Biopharm Ltd Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin
JP6948313B6 (en) 2015-09-17 2022-01-14 モデルナティエックス インコーポレイテッド Compounds and compositions for intracellular delivery of therapeutic agents
CA3001005A1 (en) 2015-10-14 2017-04-20 Bio-Path Holding, Inc. P-ethoxy nucleic acids for liposomal formulation
RU2732567C2 (en) 2015-10-16 2020-09-21 Ипсен Биофарм Лтд. Stabilized pharmaceutical compositions of camptothecin
CA3007955A1 (en) 2015-12-10 2017-06-15 Modernatx, Inc. Lipid nanoparticles for delivery of therapeutic agents
SI3394030T1 (en) 2015-12-22 2022-04-29 Modernatx, Inc. Compounds and compositions for intracellular delivery of agents
SG11201901667TA (en) 2016-09-16 2019-03-28 Bio Path Holdings Inc Combination therapy with liposomal antisense oligonucleotides
CA3040395A1 (en) 2016-11-02 2018-05-11 Ipsen Biopharm Ltd. Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin)
EP3538067A1 (en) 2016-11-08 2019-09-18 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
FI3596041T3 (en) 2017-03-15 2023-01-31 Compound and compositions for intracellular delivery of therapeutic agents
US11203569B2 (en) 2017-03-15 2021-12-21 Modernatx, Inc. Crystal forms of amino lipids
AU2018234828A1 (en) 2017-03-15 2019-09-19 Modernatx, Inc. Lipid nanoparticle formulation
WO2019184991A1 (en) * 2018-03-29 2019-10-03 中国医学科学院基础医学研究所 Application of compound or traditional chinese medicine extract in preparation of nucleic acid delivery agent, and related products
US20210108198A1 (en) * 2017-03-29 2021-04-15 Institute Of Basic Medical Sciences Chinese Academy Of Medical Sciences Application of compound or traditional chinese medicine extract in preparation of nucleic acid delivery agent and related products thereof
CA3058486A1 (en) 2017-04-19 2018-10-25 Bio-Path Holdings, Inc. P-ethoxy nucleic acids for bcl2 inhibition
US12077501B2 (en) 2017-06-14 2024-09-03 Modernatx, Inc. Compounds and compositions for intracellular delivery of agents
JP6462073B1 (en) * 2017-09-04 2019-01-30 一丸ファルコス株式会社 Method for producing pH-sensitive liposomes
RU2022103533A (en) * 2017-10-20 2022-03-10 Бионтек Рна Фармасьютикалс Гмбх (Biontech Rna Pharmaceuticals Gmbh) Preparation and storage of liposomal RNA formulations suitable for therapy
US20210113641A1 (en) * 2018-03-29 2021-04-22 Institute Of Basic Medical Sciences Chinese Academy Of Medical Sciences Extraction of plant source "medicinal soup" and manual preparation of "herbal medicine" and related products
WO2020061367A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
EP3852732A1 (en) 2018-09-19 2021-07-28 ModernaTX, Inc. Peg lipids and uses thereof
US12090235B2 (en) 2018-09-20 2024-09-17 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
US11197827B2 (en) * 2018-10-31 2021-12-14 Microsoft Technology Licensing, Llc Polynucleotide encapsulation and preservation using self-assembling membranes
TW202124360A (en) 2019-09-19 2021-07-01 美商現代公司 Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
WO2022076606A1 (en) 2020-10-06 2022-04-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
JP2023546359A (en) 2020-10-06 2023-11-02 アイオバンス バイオセラピューティクス，インコーポレイテッド Treatment of NSCLC patients with tumor-infiltrating lymphocyte therapy
AU2021401302A1 (en) 2020-12-17 2023-07-06 Iovance Biotherapeutics, Inc. Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
CA3202473A1 (en) 2020-12-17 2022-06-23 Friedrich Graf Finckenstein Treatment of cancers with tumor infiltrating lymphocytes
US11524023B2 (en) 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same
TW202308669A (en) 2021-04-19 2023-03-01 美商艾歐凡斯生物治療公司 Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
JP2024527961A (en) 2021-07-28 2024-07-26 アイオバンス バイオセラピューティクス，インコーポレイテッド Treatment of cancer patients with tumor-infiltrating lymphocyte therapy in combination with KRAS inhibitors
TW202331735A (en) 2021-10-27 2023-08-01 美商艾歐凡斯生物治療公司 Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
EP4430167A1 (en) 2021-11-10 2024-09-18 Iovance Biotherapeutics, Inc. Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
WO2023201369A1 (en) 2022-04-15 2023-10-19 Iovance Biotherapeutics, Inc. Til expansion processes using specific cytokine combinations and/or akti treatment
CN114984236B (en) * 2022-04-29 2023-03-24 深圳近邻生物科技有限公司 Response type nucleic acid delivery system, preparation method thereof and cross-linked polymer carrier

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5908635A (en) * 1994-08-05 1999-06-01 The United States Of America As Represented By The Department Of Health And Human Services Method for the liposomal delivery of nucleic acids
US5885613A (en) * 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US6210707B1 (en) 1996-11-12 2001-04-03 The Regents Of The University Of California Methods of forming protein-linked lipidic microparticles, and compositions thereof
US7244826B1 (en) 1998-04-24 2007-07-17 The Regents Of The University Of California Internalizing ERB2 antibodies
US6794128B2 (en) 1998-04-24 2004-09-21 The Regents Of The University Of California Methods of selecting internalizing antibodies
US7780882B2 (en) * 1999-02-22 2010-08-24 Georgetown University Simplified and improved method for preparing an antibody or an antibody fragment targeted immunoliposome for systemic administration of a therapeutic or diagnostic agent
DE602004027655D1 (en) * 2003-11-03 2010-07-22 Yissum Res Dev Co METHOD FOR SELECTING CATIONIC OR ANIONIC LIPOSOMES FOR THE TREATMENT OF A TREATMENT MASK AND THIS SET
JP4651276B2 (en) * 2003-11-12 2011-03-16 テルモ株式会社 Antibodies that excrete liposomes from the body and liposome blood clearance promoters
JP3941808B2 (en) 2004-10-28 2007-07-04 株式会社日立製作所 Moving image change point detection method and apparatus
US20070171077A1 (en) 2006-01-26 2007-07-26 Behrouz Kawarizadeh License Plate Incorporating RFID Device
DE602008006684D1 (en) * 2007-02-09 2011-06-16 Nat Univ Corp Nara Inst C70 FULLER-INCLUDING LIPOSOM, PROCESS FOR ITS PREPARATION AND ITS USE
NZ579644A (en) 2007-02-16 2012-05-25 Merrimack Pharmaceuticals Inc Antibodies against erbb3 and uses thereof
CA2702103A1 (en) 2007-10-12 2009-04-16 Novosom Ag Improvements in or relating to amphotaric liposomes comprising neutral lipids
EP2207903A4 (en) * 2007-11-09 2012-02-15 Univ Northeastern SELF-STORING MICRICOUS NANOPARTICLES FOR SYSTEMIC GENERIC INTRODUCTION
WO2010045512A2 (en) * 2008-10-16 2010-04-22 Mdrna , Inc. Processes and compositions for liposomal and efficient delivery of gene silencing therapeutics
JP5532635B2 (en) * 2009-03-11 2014-06-25 凸版印刷株式会社 Gene analysis method and gene analysis kit using nucleic acid-containing liposome
WO2010125544A1 (en) 2009-04-30 2010-11-04 Genetic Immunity Kft. Immunogenic nanomedicine composition and preparation and uses thereof
US8420118B2 (en) * 2009-09-10 2013-04-16 The Board Of Regents Of The University Of Oklahoma Anionic lipids and lipid nano-structures and methods of producing and using same

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DEWA, T. ET AL.: "Liposomal polyamine-dialkyl phosphate conjugates as effective gene carriers: chemical structure, morphology, and gene transfer activity", BIOCONJUG. CHEM., vol. 21, no. 5, 19 May 2010 (2010-05-19), pages 844 - 852, XP055015153 *
DRAKE, C. R. ET AL.: "Bioresponsive small molecule polyamines as noncytotoxic alternative to polyethylenimine", MOL. PHARM., vol. 7, no. 6, 6 December 2010 (2010-12-06), pages 2040 - 2055, XP055120070 *
ELIYAHU, H. ET AL.: "Dextran-spermine-based polyplexes-evaluation of transgene expression and of local and systemic toxicity in mice", BIOMATERIALS, vol. 27, no. 8, March 2006 (2006-03-01), pages 1636 - 1645, XP027950920 *
GHONAIM, H. M. ET AL.: "Very long chain N4, N9 -diacyl spermines: non-viral lipopolyamine vectors for efficient plasmid DNA and siRNA delivery", PHARM. RES., vol. 26, no. 1, January 2009 (2009-01-01), pages 19 - 31, XP019647952 *
RANDAZZO, R. A. ET AL.: "A series of cationic sterol lipids with gene transfer and bactericidal activity", BIOORG. MED. CHEM., vol. 17, no. 9, 1 May 2009 (2009-05-01), pages 3257 - 3265, XP026022767 *

Also Published As

Publication number Publication date
EP2675918A2 (en) 2013-12-25
US10087464B2 (en) 2018-10-02
US20160138044A1 (en) 2016-05-19
CA2827118A1 (en) 2012-08-23
JP6313406B2 (en) 2018-04-18
US20140065204A1 (en) 2014-03-06
EP2675918B1 (en) 2017-11-08
AU2012217685B2 (en) 2017-05-18
AU2012217685A1 (en) 2013-08-22
JP6054308B2 (en) 2016-12-27
EP2675918A4 (en) 2015-06-03
WO2012112730A2 (en) 2012-08-23
JP2014508518A (en) 2014-04-10
US20190017073A1 (en) 2019-01-17
JP2017093436A (en) 2017-06-01

Similar Documents

Publication Publication Date Title
WO2012112730A3 (en) Compositions and methods for delivering nucleic acid to a cell
IL288509A (en) Mammalian cell culture
HRP20181657T1 (en) Method of producing recombinant adamts13 in cell culture
HRP20190484T1 (en) Cell culture compositions and methods for polypeptide production
WO2011071860A3 (en) Compositions for nucleic acid delivery
EP2656397A4 (en) Method for connecting solar cells
MX2015002990A (en) Fad2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks.
EP2729561A4 (en) Cell culture process
IL222454A0 (en) Improved cell cultivation process
EP2545178A4 (en) Acid production by fermentation
WO2012166425A3 (en) Methods of amplifying whole genome of a single cell
EP3144319B8 (en) Cell culture composition comprising laminin-521
EP2698852A4 (en) Solid electrolyte fuel cell
WO2012103261A3 (en) Compositions and methods for succinate production
ZA201402046B (en) Nucleic acid enzyme substrates
EP2632931A4 (en) Compositions and methods for specific cleavage of exogenous rna in a cell
WO2012106089A3 (en) 3d cell viability assay
WO2012068038A3 (en) Caffeic acid derivatives and their use in improving neuronal cell viability
WO2012103263A3 (en) Compositions and methods for malate and fumarate production
WO2011106401A3 (en) Methods and compositions relating to multiciliate cell differentiation
AU2011903899A0 (en) Cell culture & expansion
GB201020075D0 (en) Mammalian cell transformation method
IL226038A0 (en) Compositions and methods for specific cleavage of exogenous rna in a cell
AU2011903686A0 (en) Nucleic acid enzyme substrates
GB201007863D0 (en) Bioreactor for cell culture

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2827118

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2013553671

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2012217685

Country of ref document: AU

Date of ref document: 20120215

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2012746634

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2012746634

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载